LianBio Entered into a Clinical Supply Agreement with AstraZeneca to Evaluate BBP-398 + Osimertinib for Non-Small Cell Lung Cancer with EGFR Mutations
Shots:
- The companies collaborated to evaluate BBP-398 (SHP2 inhibitor) + AstraZeneca’s osimertinib (EGFR) inhibitor in the P-I study incl. a dose escalation phase, followed by expansion cohorts for NSCLC with EGFR mutations
- The trial focuses to evaluate the safety, tolerability, PK & anti-tumor activity of BBP-398 + osimertinib. The trial is expected to be initiated in H2’23
- LianBio & BridgeBio collaborated for BBP-398 with various agents in solid tumors i.e., NSCLC, colorectal & pancreatic cancer in mainland China & other Asian markets. BBP-398 is being studied by BridgeBio & its clinical collaborators, incl. BMS for use with Opdivo & with Amgen for combination with Lumakras for advanced solid tumors
Ref: LianBio | Image: LianBio
Related News:- LianBio Reports the NMPA Acceptance of NDA and Granted Priority Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
